Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) is expected to release its earnings data before the market opens on ...
Terns Pharmaceuticals (TERN – Research Report) received a Hold rating and price target from William Blair analyst Andy Hsieh today. The ...
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...
Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a ...
Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertiseFOSTER CITY, Calif., Feb. 20, ...
William Blair initiated coverage of Terns Pharmaceuticals (TERN) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...
Equities researchers at William Blair started coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) in a research note issued to investors on Friday, Marketbeat reports. The firm ...
Terns Pharmaceuticals ( ($TERN) ) has issued an announcement. On February 22, 2025, Terns Pharmaceuticals announced the appointment of Andrew ...
Seasoned public company CFO with 25 years of leadership experience in biotechFOSTER CITY, Calif., Feb. 24, 2025 (GLOBE ...
FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule ...
FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage ...